Literature DB >> 15880468

Quantitative analysis of the "warm-up" phenomenon in myotonic dystrophy type 1.

E L Logigian1, C L Blood, N Dilek, W B Martens, R T Moxley, A W Wiegner, C A Thornton, R T Moxley.   

Abstract

To quantitate improvement in hand-grip myotonia and muscle strength (i.e., the "warm-up" phenomenon) in myotonic dystrophy type 1 (DM1), six successive, standardized maximum voluntary isometric contractions (MVICs) were recorded on 2 separate days using a computerized isometric hand-grip myometer in 25 genetically confirmed DM1 patients and in 17 normal controls. An automated computer program placed cursors along the declining (relaxation) phase of the MVICs at 90%, 50%, and 5% of peak force (PF) and calculated relaxation times (RTs) between these points. Mean 90% to 5% RT (a measure of myotonia) rapidly declined from 2.5 s in MVIC 1 to 0.8 s in MVIC 6 (warm-up = 1.7 s) in DM1; in controls, it remained 0.4 s for all six MVICs (warm-up = 0). In DM1, 70% of warm-up occurred between MVIC 1 and 2, almost exclusively in the terminal 50% to 5% phase of muscle relaxation. Day 1 warm-up was highly correlated with the severity of myotonia, and with day 2 warm-up. Improvement in myotonia was not accompanied by either transient paresis or improvement in PF. We conclude that, with this testing paradigm: warm-up of myotonia in DM1 can be reliably measured; is proportional to severity of myotonia; occurs rapidly, being most prominent between the first and second grips; mainly results from shortening of the terminal phase of muscle relaxation; and is not accompanied by significant warm-up in force output.

Entities:  

Mesh:

Year:  2005        PMID: 15880468     DOI: 10.1002/mus.20339

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  17 in total

1.  Myotonic dystrophy health index: Correlations with clinical tests and patient function.

Authors:  Chad Heatwole; Rita Bode; Nicholas E Johnson; Jeanne Dekdebrun; Nuran Dilek; Katy Eichinger; James E Hilbert; Eric Logigian; Elizabeth Luebbe; William Martens; Michael P Mcdermott; Shree Pandya; Araya Puwanant; Nan Rothrock; Charles Thornton; Barbara G Vickrey; David Victorson; Richard T Moxley
Journal:  Muscle Nerve       Date:  2015-12-29       Impact factor: 3.217

2.  Electromechanical delays during a fatiguing exercise and recovery in patients with myotonic dystrophy type 1.

Authors:  Fabio Esposito; Emiliano Cè; Susanna Rampichini; Elena Monti; Eloisa Limonta; Barbara Fossati; Giovanni Meola
Journal:  Eur J Appl Physiol       Date:  2017-02-14       Impact factor: 3.078

3.  Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1.

Authors:  E L Logigian; W B Martens; R T Moxley; M P McDermott; N Dilek; A W Wiegner; A T Pearson; C A Barbieri; C L Annis; C A Thornton; R T Moxley
Journal:  Neurology       Date:  2010-05-04       Impact factor: 9.910

4.  Open-label trial of recombinant human insulin-like growth factor 1/recombinant human insulin-like growth factor binding protein 3 in myotonic dystrophy type 1.

Authors:  Chad R Heatwole; Katy J Eichinger; Deborah I Friedman; James E Hilbert; Carlayne E Jackson; Eric L Logigian; William B Martens; Michael P McDermott; Shree K Pandya; Christine Quinn; Alexis M Smirnow; Charles A Thornton; Richard T Moxley
Journal:  Arch Neurol       Date:  2010-09-13

5.  The Change of Grip Strength in a Patient with Congenital Myotonic Dystrophy Over a 4-year Period.

Authors:  Shin Kikuchi; Naoki Kozuka; Eiji Uchida; Takafumi Ninomiya; Haruyuki Tatsumi; Hidekatsu Takeda; Nobutada Tachi
Journal:  J Jpn Phys Ther Assoc       Date:  2008

6.  Muscleblind1, but not Dmpk or Six5, contributes to a complex phenotype of muscular and motivational deficits in mouse models of myotonic dystrophy.

Authors:  Anna Matynia; Carina Hoi Ng; Warunee Dansithong; Andy Chiang; Alcino J Silva; Sita Reddy
Journal:  PLoS One       Date:  2010-03-25       Impact factor: 3.240

7.  Evoked myotonia can be "dialed-up" by increasing stimulus train length in myotonic dystrophy type 1.

Authors:  Eric L Logigian; Paul Twydell; Nuran Dilek; William B Martens; Chris Quinn; Allen W Wiegner; Chad R Heatwole; Charles A Thornton; Richard T Moxley
Journal:  Muscle Nerve       Date:  2010-02       Impact factor: 3.217

Review 8.  Clinical evaluation of membrane excitability in muscle channel disorders: potential applications in clinical trials.

Authors:  James C Cleland; Eric L Logigian
Journal:  Neurotherapeutics       Date:  2007-04       Impact factor: 7.620

9.  A quantitative measure of handgrip myotonia in non-dystrophic myotonia.

Authors:  Jeffrey M Statland; Brian N Bundy; Yunxia Wang; Jaya R Trivedi; Dipa Raja Rayan; Laura Herbelin; Merideth Donlan; Rhonda McLin; Katy J Eichinger; Karen Findlater; Liz Dewar; Shree Pandya; William B Martens; Shannon L Venance; Emma Matthews; Anthony A Amato; Michael G Hanna; Robert C Griggs; Richard J Barohn
Journal:  Muscle Nerve       Date:  2012-10       Impact factor: 3.217

10.  Clinical, pathological and genetic characteristics of a pedigree with myotonic dystrophy type 1.

Authors:  Qing Liu; Yu-Fei Zheng; Yan-Ping Zhu; Shi-Qing Ling; Wei-Rong Li
Journal:  Exp Ther Med       Date:  2015-09-09       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.